The forecast for anti-infective medicine sales in Sweden indicates a steady increase over the next five years, with values rising from $393.7 million in 2024 to $399.3 million in 2028. In 2023, the value stood at $392.0 million. The year-on-year variations show incremental growth, highlighting a modest but stable increase in interest and investment in anti-infective medicines. Over the past two years, an approximate annual growth rate of 0.4% was observed, and the five-year CAGR suggests a gradual upward trend.
Future trends to watch for include:
- The impact of new anti-infective drug introductions and innovative treatments on market growth.
- Changes in disease prevalence, particularly resistant strains, which could drive higher demand.
- Policy and regulatory changes influencing drug pricing and healthcare funding.
- Potential market disruptions from emerging global health threats and pandemic preparedness measures.
